Stock IPH INNATE PHARMA
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Innate Pharma

Equities

IPH

FR0010331421

Market Closed - Euronext Paris
Other stock markets
 11:35:00 2024-05-15 am EDT 		After market 02:40:38 pm
2.35 EUR +1.08% Intraday chart for Innate Pharma 2.35 0.00%
Apr. 15 Sanofi: progress in hematology trial CF
Apr. 15 Innate Pharma: progress in hematology trial CF

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
BU
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
BU
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
BU
Innate Pharma : Notice of Convening 2024
PU
Innate Pharma : Brochure AG
PU
Innate Pharma : Report of the Executive Board at the Annual Shareholder's Meeting of May 2024
PU
Innate Pharma : Table of Financial Resolutions 2024
PU
Innate Pharma : Extraordinary and Ordinary General Meeting
PU
INNATE PHARMA ANNOUNCES ADVANCEMENT OF SANOFI-DEVELOPED NK CELL ENGAGER SAR443579/IPH6101 PROGRESSING TO PHASE 2 FOR BLOOD CANCER PATIENTS
AQ
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
BU
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
BU
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
BU
Innate Pharma Announces Its Participation in Upcoming Investor Conference
BU
INNATE PHARMA FILES ITS 2023 UNIVERSAL REGISTRATION DOCUMENT AND 2023 ANNUAL REPORT ON FORM 20-F
AQ
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
BU
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
BU
Innate Pharma Announces Its Participation to Upcoming Investor Conference
BU
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
BU
INNATE PHARMA SA - FIRST PATIENT DOSED IN PHASE 1/2 STUDY OF IPH6501 IN RELAPSED, REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
AQ
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IPH Stock
  4. News Innate Pharma
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW